EIP Pharma, LLC

8 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

May 2032

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Mar 24, 2027
The maintenance fee for Compositions and methods for treating dementia (US 10,420,770) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

Patent	Title	Status	Expires	Confidence
US 8,697,627	Compositions and methods for treating alzheimer's disease In force Term ends May 9, 2032 · From the USPTO record	In force	Term ends May 9, 2032	From the USPTO record
US 9,427,438	Compositions and methods for treating Alzheimer's disease In force Ends no later than May 9, 2032 · From the USPTO record	In force	Ends no later than May 9, 2032	From the USPTO record
US 9,579,322	Methods for treating neurologic disorders In force Term ends Jul 8, 2035 · From the USPTO record	In force	Term ends Jul 8, 2035	From the USPTO record
US 9,427,439	Methods and compositions for recovery from stroke In force Term ends Oct 26, 2035 · From the USPTO record	In force	Term ends Oct 26, 2035	From the USPTO record
US 10,420,770	Compositions and methods for treating dementia In force Term ends Apr 21, 2037 · From the USPTO record	In force	Term ends Apr 21, 2037	From the USPTO record
US 11,466,008	Co-crystals of neflamapimod (VX-745) In force Term ends Sep 18, 2038 · From the USPTO record	In force	Term ends Sep 18, 2038	From the USPTO record
US 10,653,695	Pharmaceutical formulations of neflamapimod In force Term ends Mar 12, 2039 · From the USPTO record	In force	Term ends Mar 12, 2039	From the USPTO record
US 12,734,174	Treatment of a Selective Population of Patients Having Dementia with Lewy Bodies In force Ends no later than Nov 4, 2042 · Medium confidence	In force	Ends no later than Nov 4, 2042	Medium confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 1 abandoned · 4 no status recorded

List them